Harbin Gloria Pharmaceuticals (002437) fair value: what the stock is really worth
As of Sep 22, 2026: fair value of Harbin Gloria Pharmaceuticals ¥1.90, price ¥3.78, upside -49.7%, quality 69 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Harbin Gloria Pharmaceuticals for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ¥1.68 – ¥4.98 · fair‑value band ¥1.36 – ¥2.56 · the ¥3.78 price screens above the ¥1.90 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 24, 2026.
Follow Harbin Gloria Pharmaceuticals in your weekly email
Every Wednesday you see whether Harbin Gloria Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
HARBIN GLORIA PHARMACEUTICALS Co., LTD engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. Its products include cardiovascular and cerebrovascular, musculoskeletal, vitamins, electrolyte, diabetes-lowering, analgesics, digestive system and metabolism, anti-infective, and anti-tumor drugs.
Show more
HARBIN GLORIA PHARMACEUTICALS Co., LTD engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. Its products include cardiovascular and cerebrovascular, musculoskeletal, vitamins, electrolyte, diabetes-lowering, analgesics, digestive system and metabolism, anti-infective, and anti-tumor drugs. Harbin Gloria Pharmaceuticals Co., Ltd was founded in 2000 and is based in Harbin, the People's Republic of China.
Stock analysis
Harbin Gloria Pharmaceuticals (002437) currently trades at ¥3.78, while our model-based Fair Value estimate is ¥1.90, implying the stock looks roughly 99.0% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ¥2.97 per share, and 0 of the 25 models we run sit above the ¥3.78 price.
Bear case: the Asset-Based group reads lowest at ¥0.6900, and 25 of the 25 models stay below the price. Evidence for this calculation is low.
Scenario range: ¥1.36 (bear) to ¥2.56 (bull), the price of ¥3.78 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 69/100 (solid quality), in the Healthcare sector.
Mixed Growth: Spin-off in 2025: revenue and profit before it include the divested business. Growth is measured afresh from 2025.
Harbin Gloria Pharmaceuticals reported revenue of 2.1B CNY in FY2025 versus 3.1B CNY in FY2021, a compound −9.2%/yr. Reported net income was 377M CNY in FY2025, compounding +70.1%/yr from FY2021.
Key figures
Market cap 8.4B CNY (≈ $1.3B) · P/E ratio 21.0 · P/S ratio 3.71 · EPS (TTM) ¥0.1800 · Dividend yield 0.0% · Net margin 17.6% · Return on equity 19.1% · Return on assets (EBIT) 3.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (low confidence).
What moves the price
The share trades about 24% below its 52-week high and 56% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −50%, 002437 screens richer than that median.
Fair Value models
Bear ¥1.36Fair Value ¥1.90Bull ¥2.56
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (¥0.1317 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.55/100
Spin-off in 2025: revenue and profit before it include the divested business. Growth is measured afresh from 2025.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.5%
Revenue growth 17 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
≈ −4.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−4.7%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.11% vs −6%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.19% → 13%
Start year 2020 (pandemic)
⚠ Rate on operating basis: 2025 sits 114% above its own trend.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+20.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +18.4% a year for the price.
Compare Harbin Gloria Pharmaceuticals with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 626 stocks
Beats the industry median on 10/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score69 · Top 25%
Fair Value upside−50% · Below median
Profitability
Return on equity (TTM)19% · Top 25%
Return on assets5% · Above median
Net margin (TTM)19% · Top 25%
Operating margin (TTM)14% · Above median
Growth and dividend
Revenue growth−2% · Below median
Dividend yield (TTM)0.0% · Bottom 25%
Balance sheet
Debt / equity0.00× · Lowest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (TTM)21.0× · Cheaper than median
P/B0.55× · Cheapest 25%
P/S (TTM)0.59× · Cheapest 25%
P/FCF5.0× · Pricier than median
EV/EBITDA2.6× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 14
FUTURE (revenue growth)0· sector 21
PAST (return on equity)76· sector 27
HEALTH (low debt)100· sector 96
DIVIDEND (yield)0· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Harbin Gloria Pharmaceuticals (002437) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ¥1.90 versus a price of ¥3.78, about −50% upside (overvalued).
What is the fair value of 002437?
Our model-based fair value for Harbin Gloria Pharmaceuticals is ¥1.90 (as of Sep 24, 2026), built from audited fundamentals. The current price: ¥3.78.
What is the quality score of 002437?
Harbin Gloria Pharmaceuticals has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Harbin Gloria Pharmaceuticals (002437)?
Our model-based price target is the fair value of ¥1.90 (as of Sep 24, 2026) from 25 valuation models. Cautious scenario ¥1.36, optimistic scenario ¥2.56. It is a calculation from audited fundamentals, not an analyst target.
What is the Harbin Gloria Pharmaceuticals stock forecast for 2026?
Our models put fair value at ¥1.90, about −50% upside versus a price of ¥3.78 (overvalued). Cautious scenario ¥1.36, optimistic scenario ¥2.56. The calculation is refreshed regularly with new filings.
What is the revenue of Harbin Gloria Pharmaceuticals (002437)?
Harbin Gloria Pharmaceuticals reported trailing-twelve-month revenue of about 2.1B CNY (latest available figure, as of Sep 24, 2026).
Does Harbin Gloria Pharmaceuticals pay a dividend?
Harbin Gloria Pharmaceuticals currently shows a dividend yield of about 0.02% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Harbin Gloria Pharmaceuticals (002437)?
For today's price to be fair in a discounted-cash-flow model, Harbin Gloria Pharmaceuticals would have to grow free cash flow by +20.4 % per year for five years (discount rate 10.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -6.9 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 002437 use?
Our models discount Harbin Gloria Pharmaceuticals at 10.4 %: a base by market capitalisation (small), damped by beta 0.11, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Harbin Gloria Pharmaceuticals that is +20.4 % per year a year over ten years, using the same discount rate (10.4 %) and the same formula as our fair value.
How much growth has Harbin Gloria Pharmaceuticals (002437) delivered so far?
Over the past 5 years revenue at Harbin Gloria Pharmaceuticals grew -6.9 % a year. The price currently implies +20.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Harbin Gloria Pharmaceuticals (002437) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Harbin Gloria Pharmaceuticals (+20.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Harbin Gloria Pharmaceuticals (002437)?
The free-cash-flow yield on the price is 2.96 %: that much free cash flow Harbin Gloria Pharmaceuticals produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Harbin Gloria Pharmaceuticals (002437)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Harbin Gloria Pharmaceuticals it is ¥1.90 per share (as of Sep 24, 2026), against a price of ¥3.78. It is the blended result of 25 valuation models (cash flow, earnings, asset, dividend).
Is Harbin Gloria Pharmaceuticals stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 002437 trades above its calculated fair value: price ¥3.78, fair value ¥1.90, a gap of about −50% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 002437?
No. The price is what the market pays today (¥3.78); the fair value is what the company's own numbers justify (¥1.90). For Harbin Gloria Pharmaceuticals the two are ¥1.88 per share apart. That gap is exactly why we show both numbers side by side.
How much is Harbin Gloria Pharmaceuticals worth?
The market values Harbin Gloria Pharmaceuticals at about 8.4B CNY (market capitalisation, as of Sep 24, 2026). Per share that is ¥3.78; our models calculate a fair value of ¥1.90 per share.
What do the bullish and bearish scenarios say about 002437?
Our models span a range for Harbin Gloria Pharmaceuticals: cautious scenario ¥1.36, base ¥1.90, optimistic ¥2.56 per share (as of Sep 24, 2026, price ¥3.78). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 002437?
Harbin Gloria Pharmaceuticals trades at a price-to-earnings ratio of 21.0 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥1.90 is built from several models across several years. Other multiples: P/B 0.6, P/S 0.6, EV/EBITDA 2.6.
How solid is the balance sheet of Harbin Gloria Pharmaceuticals (002437)?
Balance-sheet figures for Harbin Gloria Pharmaceuticals (as of Sep 24, 2026): return on equity 19.1%, debt of 0.00 per unit of equity. They feed the Quality Score of 69/100, which measures business quality independently of the share price.
How far is 002437 from its 52-week high?
Harbin Gloria Pharmaceuticals trades at ¥3.78, about 24% below its 52-week high of ¥4.98 and 56% above the low of ¥2.43 (as of Sep 22, 2026). Distance from the high says nothing about value: that is what the fair value of ¥1.90 is for.
Which stocks are comparable to Harbin Gloria Pharmaceuticals?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Harbin Gloria Pharmaceuticals stock attractive at the current price?
The data as of Sep 24, 2026: price ¥3.78, calculated fair value ¥1.90 (−50%), Quality Score 69/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 002437 calculated?
We run Harbin Gloria Pharmaceuticals through 25 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥1.90, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Harbin Gloria Pharmaceuticals itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Harbin Gloria Pharmaceuticals (002437)?
The closing price on Sep 22, 2026 was ¥3.78. Our model-based fair value is ¥1.90, about −50% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Harbin Gloria Pharmaceuticals right now?
The price sits above even our optimistic bull case (¥2.56). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (69/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (¥1.36 to ¥2.56) leaves room in how you read the outcome.
Where does the earnings growth of Harbin Gloria Pharmaceuticals (002437) come from?
Earnings per share at Harbin Gloria Pharmaceuticals grew −9.6 % a year from 2013 to 2024. Broken into its drivers: revenue per share +2.3 %, EBIT margin −10.0 %, tax rate −0.5 %, residual (interest, one-offs) −1.3 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Harbin Gloria Pharmaceuticals
How large is the market capitalisation of Harbin Gloria Pharmaceuticals (002437)?
The market capitalisation of Harbin Gloria Pharmaceuticals is 8.4B CNY (≈ $1.3B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Harbin Gloria Pharmaceuticals (002437)?
The price-to-sales ratio of Harbin Gloria Pharmaceuticals is 3.71 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Harbin Gloria Pharmaceuticals (002437)?
Earnings per share at Harbin Gloria Pharmaceuticals are ¥0.1800 (price ÷ EPS = P/E 21.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Harbin Gloria Pharmaceuticals (002437)?
The dividend yield of Harbin Gloria Pharmaceuticals is 0.0% (payout 0.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Harbin Gloria Pharmaceuticals (002437)?
The net margin of Harbin Gloria Pharmaceuticals is 17.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Harbin Gloria Pharmaceuticals (002437)?
The return on equity (ROE) of Harbin Gloria Pharmaceuticals is 19.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Harbin Gloria Pharmaceuticals (002437)?
On an EBIT basis the return on assets of Harbin Gloria Pharmaceuticals is 3.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Harbin Gloria Pharmaceuticals (002437)?
The operating margin of Harbin Gloria Pharmaceuticals is 14.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Harbin Gloria Pharmaceuticals (002437)?
Revenue at Harbin Gloria Pharmaceuticals is growing −2.2% versus a year earlier (3y avg −11.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Harbin Gloria Pharmaceuticals (002437)?
Earnings per share at Harbin Gloria Pharmaceuticals are growing +59.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Harbin Gloria Pharmaceuticals (002437) hold?
Harbin Gloria Pharmaceuticals holds more cash than debt, 480M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Harbin Gloria Pharmaceuticals in the live analysis
One click puts Harbin Gloria Pharmaceuticals on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
